Abstract
Several studies have reported a decline in incidence of dementia which may have large implications for the projected burden of disease, and provide important guidance to preventive efforts. However, reports are conflicting or inconclusive with regard to the impact of gender and education with underlying causes of a presumed declining trend remaining largely unidentified. The Alzheimer Cohorts Consortium aggregates data from nine international population-based cohorts to determine changes in the incidence of dementia since 1990. We will employ Poisson regression models to calculate incidence rates in each cohort and Cox proportional hazard regression to compare 5-year cumulative hazards across study-specific epochs. Finally, we will meta-analyse changes per decade across cohorts, and repeat all analysis stratified by sex, education and APOE genotype. In all cohorts combined, there are data on almost 69,000 people at risk of dementia with the range of follow-up years between 2 and 27. The average age at baseline is similar across cohorts ranging between 72 and 77. Uniting a wide range of disease-specific and methodological expertise in research teams, the first analyses within the Alzheimer Cohorts Consortium are underway to tackle outstanding challenges in the assessment of time-trends in dementia occurrence.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 931-938 |
| Number of pages | 8 |
| Journal | European Journal of Epidemiology |
| Volume | 32 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2017 |
| Externally published | Yes |
Keywords
- Alzheimer disease
- Cohort analysis
- Consortium
- Epidemiology
ASJC Scopus subject areas
- Epidemiology
Access to Document
Other files and links
Fingerprint
Dive into the research topics of 'Trends in the incidence of dementia: design and methods in the Alzheimer Cohorts Consortium'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: European Journal of Epidemiology, Vol. 32, No. 10, 01.10.2017, p. 931-938.
Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Trends in the incidence of dementia
T2 - design and methods in the Alzheimer Cohorts Consortium
AU - Chibnik, Lori B.
AU - Wolters, Frank J.
AU - Bäckman, Kristoffer
AU - Beiser, Alexa
AU - Berr, Claudine
AU - Bis, Joshua C.
AU - Boerwinkle, Eric
AU - Bos, Daniel
AU - Brayne, Carol
AU - Dartigues, Jean Francois
AU - Darweesh, Sirwan K.L.
AU - Debette, Stephanie
AU - Davis-Plourde, Kendra L.
AU - Dufouil, Carole
AU - Fornage, Myriam
AU - Grasset, Leslie
AU - Gudnason, Vilmundur
AU - Hadjichrysanthou, Christoforos
AU - Helmer, Catherine
AU - Ikram, M. Arfan
AU - Ikram, M. Kamran
AU - Kern, Silke
AU - Kuller, Lewis H.
AU - Launer, Lenore
AU - Lopez, Oscar L.
AU - Matthews, Fiona
AU - Meirelles, Osorio
AU - Mosley, Thomas
AU - Ower, Alison
AU - Psaty, Bruce M.
AU - Satizabal, Claudia L.
AU - Seshadri, Sudha
AU - Skoog, Ingmar
AU - Stephan, Blossom C.M.
AU - Tzourio, Christophe
AU - Waziry, Reem
AU - Wong, Mei Mei
AU - Zettergren, Anna
AU - Hofman, Albert
N1 - Funding Information: Funding The Alzheimer Cohorts Consortium is supported by an unrestricted grant from the Janssen Prevention Center to the Harvard T.H. Chan School of Public Health. Age, Gene/Environment Susceptibility (AGES) This study is supported by National Institute of Aging contracts (N01-AG-12100 and HHSN271201200022C) with contributions from the National Eye Institute, National Institute on Deafness and Other Communication Disorders, and the National Heart, Lung and Blood Institute, the National Institute of Aging Intramural Research Program, Hjartavernd (the Icelandic Heart Association), and the Althingi (the Icelandic Parliament); Atherosclerosis Risk in Communities (ARIC) This study is carried out as a collaborative study supported by National Heart, Lung, and Blood Institute contracts (HHSN268201100005C, HHSN2682011000 06C, HHSN268201100007C, HHSN268201100008C, HHSN2682011 00009C, HHSN268201100010C, HHSN268201100011C, and HHSN268201100012C). Neurocognitive data is collected by (U01 HL096812, HL096814, HL096899, HL096902, HL096917) with funding also provided by the National Institute of Neurologic Disorders and Stroke; Cardiovascular Health Study (CHS) This research was supported by contracts (HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086), and grants U01HL080295, U01HL130114 and HL105756 from the National Heart, Lung, and Blood Institute (NHLBI), with additional contribution from the National Institute of Neurological Disorders and Stroke (NINDS). Additional support was provided by the National Institute on Aging (R01AG023629) and, in part, by grants (AG20098, AG15928, and AG05133). The funding sources did not have any role in the study design; collection, analysis, or interpretation of data; preparation of the manuscript; or decision to submit it for publication; Funding Information: Conflict of interest Dr. Dartigues has a grant from Roche, Dr. Lopez is a consultant for Grifols, Lundbeck, and Raman Technologies and is supported by a National Institutes of Health Grant (P50 AG005133). Dr. Psaty serves on the DSMB of a clinical trial funded by Zoll LifeCor and on the Steering Committee of the Yale Open Data Access Project funded by Johnson & Johnson. Dr Hofman is supported by an unrestricted grant from the Janssen Prevention Center. All other authors report no conflict of interests. Funding Information: Council (MRC) CFAS I was funded by the MRC (Research Grant: G9901400) and the National Health Service (NHS). CFAS II has been supported by the UK Medical Research Council (Research Grant:G06010220) and received additional support from the National Institute for Health Research (NIHR), comprehensive clinical research networks in West Anglia, Nottingham City and Notting-hamshire County NHS Primary Care trusts and the dementias and neurodegenerative disease research Network (DeNDRoN) in Newcastle; Framingham Heart Study (FHS) This work was supported by the National Heart, Lung, and Blood Institute’s Framingham Heart Study (contracts N01-HC-25195 and HHSN268201500001I). This study was also supported by grants from the National Institute on Aging: (AG054076, U01-AG049505, and AG008122 (S. Seshadri)). S. Seshadri and A. Beiser were also supported by additional grants from the National Institute on Aging (R01AG049607, AG033193, AG033040) and the National Institute of Neurological Disorders and Stroke (R01-NS017950); The Gothenburg study This study was supported by grants from The Swedish Research Council 2012-5041, 2015-02830, 2013-8717, Swedish Research Council for Health, Working Life and Wellfare (no 2001-2646, 2003-0234, 2004-0150, 2006-0020, 2008-1229, 2012-1138, 2004-0145, 2006-0596, 2008-1111, 2010-0870, 2013-1202, 2001-2849, 2005-0762, 2008-1210, 2013-2300, 013-2496, Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse, Hjärnfonden, Sahlgrenska University Hospital (ALF), The Alzheimer’s Association Zenith Award (ZEN-01-3151), The Alzheimer’s Association Stephanie B. Overstreet Scholars (IIRG-00-2159), Alzheimer’s Association (IIRG-03-6168), The Alzheimer’s Association (IIRG-09-131338), Eivind och Elsa K:son Sylvans stiftelse, Stiftelsen Söderström-Königska Sjukhemmet, Stiftelsen för Gamla Tjänarinnor, Handlanden Hjalmar Svenssons Forskningsfond, Stiftelsen Professor Bror Gadelius’ Minnesfond, Swedish Alzheimer foundation; PAQUID The PAQUID cohort was supported by IPSEN France, NOVARTIS Pharma France, and the CNSA (Caisse Nationale de Solidarité et d’Autonomie). The research presented in this manuscript is original. The contents of this article are solely the responsibility of the authors. IPSEN, NOVARTIS and the CNSA did not fund this specific study. The funders had no role in the collection, management, analysis, or interpretation of the data and had no role in the preparation, review or approval of the manuscript; The Rotterdam Study This study is supported by the Erasmus Medical Centre and Erasmus University Rotterdam, The Netherlands Organization for Scientific Research (NWO), The Netherlands Organization for Health Research and Development (ZonMW), the Research Institute for Diseases in the Elderly (RIDE), The Netherlands Genomics Initiative, the Ministry of Education, Culture and Science, the Ministry of Health, Welfare and Sports, the European Commission (DG XII), and the Municipality of Rotterdam. Further support was obtained from the Netherlands Consortium for Healthy Ageing and the Dutch Heart Foundation (2012T008). This research was further supported by funding from the European Union Seventh Framework Program (FP7/2007e2013) under grant agreement no. 601055, VPH-Dare@IT (FP7-ICT-2011-9e601055); and funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 667375 (Co-STREAM) and under grant agreement no. 678543 (European Research Council (ERC) funded project: ORACLE). None of the funding organizations or sponsors were involved in study design, in collection, analysis, and interpretation of data, in writing of the report, or in the decision to submit the article for publication; The 3-Cites Study This study is conducted under a partnership agreement among the Institut National de la Santé et de la Recherche Médicale (INSERM), the Victor Segalen–Bordeaux II University, and Sanofi-Aventis. The Fondation pour la Recherche Médicale funded the preparation and initiation of the study. The 3C Study is also supported by the Caisse Nationale Maladie des Tra-vailleurs Salariés, Direction Générale de la Santé, Mutuelle Générale de l’Education Nationale (MGEN), Institut de la Longévité, Conseils Régionaux of Aquitaine and Bourgogne, Fondation de France, and Ministry of Research–INSERM Programme ‘‘Cohortes et collections de données biologiques’’; Infrastructure for the CHARGE Consortium is supported in part by National Heart, Lung and Blood Institute (HL105756) and for the neurology working group by National Institutes of Aging (AG033193 and AG049505). Publisher Copyright: © 2017, Springer Science+Business Media B.V.
PY - 2017/10/1
Y1 - 2017/10/1
N2 - Several studies have reported a decline in incidence of dementia which may have large implications for the projected burden of disease, and provide important guidance to preventive efforts. However, reports are conflicting or inconclusive with regard to the impact of gender and education with underlying causes of a presumed declining trend remaining largely unidentified. The Alzheimer Cohorts Consortium aggregates data from nine international population-based cohorts to determine changes in the incidence of dementia since 1990. We will employ Poisson regression models to calculate incidence rates in each cohort and Cox proportional hazard regression to compare 5-year cumulative hazards across study-specific epochs. Finally, we will meta-analyse changes per decade across cohorts, and repeat all analysis stratified by sex, education and APOE genotype. In all cohorts combined, there are data on almost 69,000 people at risk of dementia with the range of follow-up years between 2 and 27. The average age at baseline is similar across cohorts ranging between 72 and 77. Uniting a wide range of disease-specific and methodological expertise in research teams, the first analyses within the Alzheimer Cohorts Consortium are underway to tackle outstanding challenges in the assessment of time-trends in dementia occurrence.
AB - Several studies have reported a decline in incidence of dementia which may have large implications for the projected burden of disease, and provide important guidance to preventive efforts. However, reports are conflicting or inconclusive with regard to the impact of gender and education with underlying causes of a presumed declining trend remaining largely unidentified. The Alzheimer Cohorts Consortium aggregates data from nine international population-based cohorts to determine changes in the incidence of dementia since 1990. We will employ Poisson regression models to calculate incidence rates in each cohort and Cox proportional hazard regression to compare 5-year cumulative hazards across study-specific epochs. Finally, we will meta-analyse changes per decade across cohorts, and repeat all analysis stratified by sex, education and APOE genotype. In all cohorts combined, there are data on almost 69,000 people at risk of dementia with the range of follow-up years between 2 and 27. The average age at baseline is similar across cohorts ranging between 72 and 77. Uniting a wide range of disease-specific and methodological expertise in research teams, the first analyses within the Alzheimer Cohorts Consortium are underway to tackle outstanding challenges in the assessment of time-trends in dementia occurrence.
KW - Alzheimer disease
KW - Cohort analysis
KW - Consortium
KW - Epidemiology
UR - http://www.scopus.com/inward/record.url?scp=85031907689&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85031907689&partnerID=8YFLogxK
U2 - 10.1007/s10654-017-0320-5
DO - 10.1007/s10654-017-0320-5
M3 - Article
C2 - 29063414
AN - SCOPUS:85031907689
SN - 0393-2990
VL - 32
SP - 931
EP - 938
JO - European Journal of Epidemiology
JF - European Journal of Epidemiology
IS - 10
ER -